CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
Bharat Forge Ltd. 25/07/20241,593.85952.3007/04/2025 -40.25% 256 days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Zydus Cadila begins human clinical trials of its ZyCoV-D vaccine
Apurva Joshi
/ Categories: Trending

Zydus Cadila begins human clinical trials of its ZyCoV-D vaccine

Zydus Cadila has commenced the adaptive phase I/II human clinical trials of its plasmid DNA vaccine, ZyCoV-D with the first human dosing. The safety, tolerability and immunogenicity of the vaccine will be assessed later on.

Earlier this month, the company had announced that its plasmid DNA vaccine candidate (ZyCoV-D) developed at its Vaccine Technology Centre (VTC) in Ahmedabad, had successfully completed the preclinical phase and also, received permission from Drug Controller General of India - Central Drugs Standard Control Organisation (CDSCO) to initiate adaptive phase I/II clinical trials in India.

In the adaptive phase I/II clinical trials, Zydus will enroll over 1,000 subjects across its multiple clinical study sites in India. It has already manufactured clinical GMP batches of the vaccine candidate for the clinical trials.

Last week, Zydus had received approval from the regulatory authority of Mexico, COFEPRIS, for its one of its lead research candidate-Desidustat to be tested in the management of COVID-19. As a part of the study, 100 mg tablets of Desidustat will be administered for a period of 14 days along with, recommended standard care, during the trial.

Zydus Cadila is putting all efforts to combat with the COVID-19 pandemic. Vaccine Technology Centre of Zydus Cadila is capable of developing and manufacturing viral, toxoid, polysaccharide, conjugate and others. Zydus was the first company in India to develop and indigenously manufacture the vaccine to combat Swine Flu during the pandemic in 2010.

On Wednesday, the stock of Cadila Healthcare opened 1.7 per cent higher at Rs 359.70 from its previous close of Rs 353.65 on BSE.

Previous Article BEL and AAI join hands for co-operation in Civil Aviation industry
Next Article Dilip Buildcon JV bags highway project worth Rs 1,900 crore
Print
3367 Rate this article:
4.4
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR